Literature DB >> 9630201

Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.

A Cömlekçi1, S Biberoglu, Z Hekimsoy, I Okan, O Pişkin, B Sekeroglu, M Alakavuklar.   

Abstract

Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains. We describe a 39-year-old normocalcemic patient with subclinical hypoparathyroidism and bone metastasis due to breast carcinoma. Following parenteral administration of 60 mg pamidronate, the corrected serum level of calcium decreased from 2.12 mmol/l (=8.9 mg/dl) to 1.42 mmol/l (5.7 mg/dl), accompanied with carpal pedal spasm. The present case indicates that the hypocalcemia due to latent hypoparathyroidism was compensated by extensive osteolysis due to bone metastasis, and that overt hypocalcemia may develop after intravenous administration of pamidronate in such a patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630201     DOI: 10.2169/internalmedicine.37.396

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Severe hypocalcaemia after being given intravenous bisphosphonate.

Authors:  Rajesh Peter; Vinita Mishra; William D Fraser
Journal:  BMJ       Date:  2004-02-07

2.  Hyperparathyroidism secondary to zoledronic acid infusion: case report.

Authors:  Meral Sayin; Gozde Yazici
Journal:  Support Care Cancer       Date:  2009-02-10       Impact factor: 3.603

3.  Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.

Authors:  A Mishra; L Wong; J Jonklaas
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

4.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.